TOP TIERMARKET NEWSWIRE

News & sentiment

INHIBRX BIOSCIENCES (INBX) — News & AI sentiment

INHIBRX BIOSCIENCES (INBX) news roundup. 6 stories aggregated over the last 30 days. Average 30-day sentiment is 57.5/100. Recent insider activity (SEC Form 4, 90-day window): 7 purchases totalling $6.3M and 2 sales totalling $279K — net buying of $6.1M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

0

30d stories

6

avg sentiment 57.5/100

Insider net (90d)

$6.1M

7 buys · 2 sells

Congress (90d)

0

0 buys · 0 sells

INBX news in the last 24 hours, 7 days, 30 days and 90 days

How much INBX coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	INBX stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	0	—	no coverage
Last 30 days	6	57.5/100	INBX headlines →
Last 90 days	31	59.8/100	INBX headlines →

Latest stories on INBX

Inhibrx Announces Participation in Upcoming Scientific Conferences

PR Newswire53 · neutralproduct/pr

Oct 13

Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup

MarketBeat67 · bullishgeneral

Oct 2

Inhibrx CEO buys $998.8K in common stock as part of option exercise

The Fly56 · neutralgeneral

Sep 28

Inhibrx Biosciences Updates Investor Presentation and Pipeline Outlook

TipRanks55 · neutralproduct/pr

Sep 28

Inhibrx Biosciences, Inc. (INBX) files 8-K

SEC 8-K50 · neutralgeneral

Sep 28

Alpha-1 Antitrypsin Deficiency Market Set for Robust Growth Driven by Innovation and Pipeline Advances by 2036 – DelveInsight | Grifols, Kamada Pharma, Takeda, Arrowhead Pharma, Mereo BioPharma

Barchart64 · neutralgeneral

Sep 28

Inhibrx director buys $500K in common stock

The Fly56 · neutralgeneral

Sep 23

Citizens reiterates Market Perform on Inhibrx Biosciences stock

Investing.com Analyst Ratings50 · neutralanalyst

Sep 18

Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?

Yahoo Finance67 · bullishgeneral

Sep 16

Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?

The Motley Fool67 · bullishgeneral

Sep 16

Inhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106

Seeking Alpha73 · bullishproduct/pr

Sep 14

Inhibrx, Eikon rise after insider buying

Seeking Alpha63 · neutralgeneral

Sep 9

H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy

Investing.com Analyst Ratings61 · neutralanalyst

Sep 9

Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom

Seeking Alpha63 · neutralproduct/pr

Sep 9

Inhibrx Biosciences reports strong Phase 2 INBRX-106 data

TipRanks73 · bullishproduct/pr

Sep 8

Inhibrx Biosciences, Inc. (INBX) files 8-K

SEC 8-K50 · neutralgeneral

Sep 8

Inhibrx cancer therapy outperforms Merck’s Keytruda in mid-stage trial

Seeking Alpha73 · bullishproduct/pr

Sep 8

Inhibrx Shares Rise After Positive Phase 2 Head and Neck Cancer Data

InvestorsHub67 · bullishproduct/pr

Sep 8

Inhibrx stock jumps on positive cancer drug trial results

Investing.com Markets73 · bullishproduct/pr

Sep 8

Inhibrx’s INBRX-106 achieves clinical benefit in Phase 2 HNSCC study

The Fly73 · bullishproduct/pr

Sep 8

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

PR Newswire76 · bullishproduct/pr

Sep 8

Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study

PR Newswire59 · neutralproduct/pr

Sep 4

Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study

StockTitan59 · neutralproduct/pr

Sep 4

Citizens reiterates Market Perform on Inhibrx Biosciences stock

Investing.com Analyst Ratings50 · neutralanalyst

Aug 27

INBX, Inhibrx Biosciences | IBD Stock Checkup

Investors.com50 · neutralgeneral

Aug 24

Open INBX in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →